These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 24449672)

  • 1. Healthcare costs and adherence associated with human regular U-500 versus high-dose U-100 insulin in patients with diabetes.
    Eby EL; Zagar AJ; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
    Endocr Pract; 2014 Jul; 20(7):663-70. PubMed ID: 24449672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis.
    Eby EL; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
    J Med Econ; 2013; 16(4):529-38. PubMed ID: 23363330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Patterns and Characteristics of Individuals Initiating High-Dose Insulin for Type 2 Diabetes Mellitus.
    Chen J; Nair R; Siadaty M; Brown K; Meah Y; Taylor AD; He X; Fan L
    J Manag Care Spec Pharm; 2020 Jul; 26(7):839-847. PubMed ID: 32584684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Patterns, Adherence, and Persistence Associated With Human Regular U-500 Insulin: A Real-World Evidence Study.
    Chen J; Kao CY; He X; Fan L; Jackson JA; Juneja R
    Diabetes Spectr; 2020 Aug; 33(3):264-272. PubMed ID: 32848348
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment Patterns and Outcomes, Before and After Humulin R U-500 Initiation, Among High-Dose Type 2 Diabetes Mellitus Patients in the United States.
    Hood RC; Borra S; Fan L; Pollom RD; Huang A; Chen J
    Endocr Pract; 2021 Aug; 27(8):798-806. PubMed ID: 34089876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Patterns and Outcomes Before and After Humulin R U-500 Initiation Among US Patients with Type 2 Diabetes Previously Prescribed ≤ 200 Units/day of U-100 Insulin.
    Chen J; Borra S; Huang A; Fan L; Pollom RD; Hood RC
    Diabetes Ther; 2022 Mar; 13(3):465-479. PubMed ID: 35190970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study.
    Eby EL; Curtis BH; Gelwicks SC; Hood RC; Idris I; Peters AL; Bergenstal RM; Jackson JA
    BMJ Open Diabetes Res Care; 2015; 3(1):e000074. PubMed ID: 25969741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
    Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
    Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects.
    de la Peña A; Riddle M; Morrow LA; Jiang HH; Linnebjerg H; Scott A; Win KM; Hompesch M; Mace KF; Jacobson JG; Jackson JA
    Diabetes Care; 2011 Dec; 34(12):2496-501. PubMed ID: 21994429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes.
    Yeaw J; Lee WC; Aagren M; Christensen T
    J Manag Care Pharm; 2012; 18(1):21-32. PubMed ID: 22235952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis.
    Byfield SA; McPheeters JT; Burton TM; Nagar SP; Hackshaw MD
    J Manag Care Spec Pharm; 2015 Jun; 21(6):515-22. PubMed ID: 26011553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a Conservative Pharmacist-led U-500R Insulin Management Protocol in the Primary Care Setting.
    Dumont C; Fitzgerald L; Valdez CA
    J Prim Care Community Health; 2020; 11():2150132720973827. PubMed ID: 33218271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resource utilization and costs associated with using insulin therapy within a newly diagnosed type 2 diabetes mellitus population.
    Bell K; Parasuraman S; Raju A; Shah M; Graham J; Denno M
    J Manag Care Spec Pharm; 2015 Mar; 21(3):220-8a. PubMed ID: 25726031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
    J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial.
    Kabul S; Hood RC; Duan R; DeLozier AM; Settles J
    Health Qual Life Outcomes; 2016 Sep; 14(1):139. PubMed ID: 27716283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes.
    Eby EL; Van Brunt K; Brusko C; Curtis B; Lage MJ
    Clin Interv Aging; 2015; 10():991-1001. PubMed ID: 26124652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EFFECT OF TOTAL DAILY DOSE ON EFFICACY, DOSING, AND SAFETY OF 2 DOSE TITRATION REGIMENS OF HUMAN REGULAR U500 INSULIN IN SEVERELY INSULIN-RESISTANT PATIENTS WITH TYPE 2 DIABETES.
    Wysham C; Hood RC; Warren ML; Wang T; Morwick TM; Jackson JA
    Endocr Pract; 2016 Jun; 22(6):653-65. PubMed ID: 26789342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007; 29 Spec No():1294-305. PubMed ID: 18046929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS.
    Hirsch JD; Gonzales M; Rosenquist A; Miller TA; Gilmer TP; Best BM
    J Manag Care Pharm; 2011 Apr; 17(3):213-23. PubMed ID: 21434698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.